(Q39483732)

12 September 2017

Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study (English)

1 reference

12 September 2017

0 references

27

Steven R Meshnick

1 reference

12 September 2017

31

Chanthap Lon

1 reference

12 September 2017

1

Michele D Spring

1 reference

12 September 2017

Jessica T Lin

2

1 reference

12 September 2017

Jessica E Manning

3

1 reference

12 September 2017

Pattaraporn Vanachayangkul

4

1 reference

12 September 2017

Sok Somethy

5

1 reference

12 September 2017

Rathvicheth Bun

6

1 reference

12 September 2017

Youry Se

7

1 reference

12 September 2017

Soklyda Chann

8

1 reference

12 September 2017

Mali Ittiverakul

9

1 reference

12 September 2017

Piyaporn Sia-ngam

10

1 reference

12 September 2017

Worachet Kuntawunginn

11

1 reference

12 September 2017

Montri Arsanok

12

1 reference

12 September 2017

Nillawan Buathong

13

1 reference

12 September 2017

Suwanna Chaorattanakawee

14

1 reference

12 September 2017

Panita Gosi

15

1 reference

12 September 2017

Winita Ta-aksorn

16

1 reference

12 September 2017

Nitima Chanarat

17

1 reference

12 September 2017

Siratchana Sundrakes

18

1 reference

12 September 2017

Nareth Kong

19

1 reference

12 September 2017

Thay Kheang Heng

20

1 reference

12 September 2017

Samon Nou

21

1 reference

12 September 2017

Paktiya Teja-isavadharm

22

1 reference

12 September 2017

Sathit Pichyangkul

23

1 reference

12 September 2017

Sut Thang Phann

24

1 reference

12 September 2017

Sujata Balasubramanian

25

1 reference

12 September 2017

Jonathan J Juliano

26

1 reference

12 September 2017

Char Meng Chour

28

1 reference

12 September 2017

Satharath Prom

29

1 reference

12 September 2017

Charlotte A Lanteri

30

1 reference

12 September 2017

David L Saunders

32

1 reference

12 September 2017

language of work or name

1 reference

12 April 2015

1 reference

Lancet Infectious Diseases

12 September 2017

1 reference

12 September 2017

15

1 reference

12 September 2017

6

1 reference

12 September 2017

683-691

1 reference

Evidence of Artemisinin-Resistant Malaria in Western Cambodia

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Artemisinin Resistance in Plasmodium falciparum Malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

A molecular marker of artemisinin-resistant Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Spread of artemisinin resistance in Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Dihydroartemisinin-piperaquine failure in Cambodia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Glucose-6-phosphate dehydrogenase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Detection of four Plasmodium species in blood from humans by 18S rRNA gene subunit-based and species-specific real-time PCR assays

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Evaluation of parasite subpopulations and genetic diversity of the msp1, msp2 and glurp genes during and following artesunate monotherapy treatment of Plasmodium falciparum malaria in Western Cambodia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Optimizing the HRP-2 in vitro malaria drug susceptibility assay using a reference clone to improve comparisons of Plasmodium falciparum field isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Blackwater fever in an uncomplicated Plasmodium falciparum patient treated with dihydroartemisinin-piperaquine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Efficacy and safety of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta-analysis of randomised controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in central Vietnam

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in western, northern, and eastern Cambodia, 2011-2012: association with molecular markers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Artemisinin‐induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Pyronaridine-artesunate versus mefloquine plus artesunate for malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

Emergence of resistance to atovaquone-proguanil in malaria parasites: insights from computational modeling and clinical case reports

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970049-6

7 January 2021

10.1016/S1473-3099(15)70049-6

Identifiers

DOI

1 reference

release_scnv7eolhzaijbje7xxbxf462i

12 September 2017

0 references

1 reference